Skip to content
  • Debatforum
  • Seneste
  • Populære
  • Bruger
Temaer
  • Light
  • Dark

Kollaps
FORSIDEN
Log ind Opret konto

Genmab — April 2018

Planlagt Fastgjort Låst Flyttet Genmab
1.4k Indlæg 1 Posters 0 Visninger
  • Ældste til nyeste
  • Nyeste til ældste
  • Most Votes
Svar
  • Svar som emne
Login for at svare
Denne tråd er blevet slettet. Kun brugere med emne behandlings privilegier kan se den.
  • E Offline
    E Offline
    E_L
    wrote on sidst redigeret af
    #188

    New trial: Short Course Daratumumab in Patients With Multiple Myeloma - https://clinicaltrials.gov/ct2/show/NCT03490344

    1 Reply Last reply
    0
    • J Offline
      J Offline
      Jazzz
      wrote on sidst redigeret af
      #189

      Er der nogen der har en ide om, hvad de forskellige analytikere vurdere Genmabs pipeline til at være værd? Jeg mener, har man med et gennemsnit target på ca 1400 kun medregnet potentialet i de markedsførte produkter, eller medregner man et lille potentiale i pipeline?

      1 Reply Last reply
      0
      • M Offline
        M Offline
        Mayflower
        wrote on sidst redigeret af
        #190

        Man laver sædvanligvis en SOTP analyse, hvor hvert element vurderes med en tilhørende sandsynlighed for at det lykkes og et medfølgende topsalg.

        1 Reply Last reply
        0
        • M Offline
          M Offline
          Mayflower
          wrote on sidst redigeret af
          #191

          more or less

          1 Reply Last reply
          0
          • J Offline
            J Offline
            Jazzz
            wrote on sidst redigeret af
            #192

            Ok.. tak!

            1 Reply Last reply
            0
            • E Offline
              E Offline
              E_L
              wrote on sidst redigeret af
              #193

              My understanding is that most analysts have very little value attributed to the pipeline (if any at all) and some stated they will need to upgrade in the case of clinical success

              1 Reply Last reply
              0
              • E Offline
                E Offline
                E_L
                wrote on sidst redigeret af
                #194

                "Incyte's stock plunges, Merck shares fall after disappointing study results of melanoma treatment " Incyte's stock plunges, Merck shares fall after disappointing study results of melanoma treatment - http://www.mrknewsroom.com/news-release/oncology/incyte-and-merck-provide-update-phase-3-study-epacadostat-0

                1 Reply Last reply
                0
                • E Offline
                  E Offline
                  E_L
                  wrote on sidst redigeret af
                  #195

                  not sure if anyone saw this as Dara competition

                  1 Reply Last reply
                  0
                  • BulderB Offline
                    BulderB Offline
                    Bulder
                    wrote on sidst redigeret af
                    #196

                    Hardly. I don't think there are any studies og dara in melanoma ongoing. So not in this particular indication. But epacadostat is being tested with nivolumab in different solid cancers. Thus competition might arise in other indications. https://en.wikipedia.org/wiki/Epacadostat https://www.clinicaltrials.gov/ct2/results?cond=&term=nivolumab+epacadostat&cntry=&state=&city=&dist=&Search=Search

                    1 Reply Last reply
                    0
                    • BulderB Offline
                      BulderB Offline
                      Bulder
                      wrote on sidst redigeret af
                      #197

                      of

                      1 Reply Last reply
                      0
                      • S Offline
                        S Offline
                        Sukkeralf
                        wrote on sidst redigeret af
                        #198

                        Could have been on longer terms - but also a reminder of how hard it is to get combinations that work in the IO space

                        1 Reply Last reply
                        0
                        • S Offline
                          S Offline
                          Sukkeralf
                          wrote on sidst redigeret af
                          #199

                          and hence not get to excited before we have seen clinical data with Dara

                          1 Reply Last reply
                          0
                          • BulderB Offline
                            BulderB Offline
                            Bulder
                            wrote on sidst redigeret af
                            #200

                            Xactly. They could fail as well

                            1 Reply Last reply
                            0
                            • BulderB Offline
                              BulderB Offline
                              Bulder
                              wrote on sidst redigeret af
                              #201

                              But interestingly all 4 epa-nivo studies are sponsored by Incyte. The dara-nivo studies are sponsored by BMS.

                              1 Reply Last reply
                              0
                              • S Offline
                                S Offline
                                Sukkeralf
                                wrote on sidst redigeret af
                                #202

                                Yes thats positive - maybe because Dara is approved and epa is not.

                                1 Reply Last reply
                                0
                                • B Offline
                                  B Offline
                                  bibob
                                  wrote on sidst redigeret af
                                  #203

                                  Yes Sukkeralf and Bulder. They know Dara as a approved and very tolerated drug , but also very comparebel with other drugs.

                                  1 Reply Last reply
                                  0
                                  • BulderB Offline
                                    BulderB Offline
                                    Bulder
                                    wrote on sidst redigeret af
                                    #204

                                    Ellers noget af et program, de har kørende, Incyte. Hele 26 kombistudier med pembro, heraf flere store fase 3 studier. I alskens solide tumorer. De fleste sponseret af dem selv. https://www.clinicaltrials.gov/ct2/results?cond=&term=epacadostat+pembrolizumab&cntry=&state=&city=&dist=

                                    1 Reply Last reply
                                    0
                                    • Helge_LarsenPI-redaktørH Offline
                                      Helge_LarsenPI-redaktørH Offline
                                      Helge_LarsenPI-redaktør
                                      wrote on sidst redigeret af
                                      #205

                                      G0d morgen. 🙂

                                      1 Reply Last reply
                                      0
                                      • B Offline
                                        B Offline
                                        bibob
                                        wrote on sidst redigeret af
                                        #206

                                        God morgen. 🙂

                                        1 Reply Last reply
                                        0
                                        • H Offline
                                          H Offline
                                          Her_for_at_lære
                                          wrote on sidst redigeret af
                                          #207

                                          Meget afdæmpet effekt af et positivt c25 på Genmab aktien?

                                          1 Reply Last reply
                                          0

                                          Hello! It looks like you're interested in this conversation, but you don't have an account yet.

                                          Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.

                                          With your input, this post could be even better 💗

                                          Tilmeld Log ind

                                          • Log ind

                                          • Har du ikke en konto? Tilmeld

                                          • Login or register to search.
                                          • First post
                                            Last post
                                          0
                                          • Debatforum
                                          • Seneste
                                          • Populære
                                          • Bruger